Sexual Health Is Health. It Shouldn't Be a Luxury.

the billionaires figured something out

A recent New Yorker piece profiled a concierge gynecologist whose patient list reads like a Silicon Valley cap table. Her clients pay tens of thousands of dollars a year for what turns out to be a fairly simple idea, taken seriously: that sexual health is a genuine part of overall health, not a vanity add-on you're supposed to be too embarrassed to raise.

The clinic's guiding line, quoted in the piece, is four words long: "Sexual health is health." She treats low desire the way a good internist treats blood pressure. It's a real thing, with real causes and real options, worth the same attention as anything else on the chart.

That framing is worth borrowing. Not the price tag. The framing.

the philosophy travels. the price tag doesn't have to.

Here's the uncomfortable part. When someone with unlimited resources says their desire has flatlined, they get a workup, a plan, and a follow-up. When most women say the same thing, they get told it's stress, or age, or just a phase every couple goes through. The symptom is identical. The response depends on your bank balance.

Low desire is not a personality trait or a life sentence. For a meaningful number of women it's a distinct, nameable issue: desire that has dropped for no clear reason, in a way that genuinely bothers them. Clinicians call it hypoactive sexual desire disorder. It's common, and it has actual causes worth sorting through, from hormones to medications to the plain biology of how desire is wired. None of that requires a membership fee to investigate.

the tool the article never mentions

The New Yorker story is about a philosophy of care, not a specific prescription, and it never names the FDA-approved, on-demand medication built for exactly this problem. So here it is on its own merits.

PT-141 (bremelanotide) was approved by the FDA in 2019 for generalized hypoactive sexual desire disorder in premenopausal women. It's the rare desire treatment that works on demand and through the brain rather than the bloodstream. It activates melanocortin pathways in the central nervous system that help regulate sexual desire, a completely different mechanism than the blood-flow drugs marketed to men. In the Phase 3 RECONNECT trials of roughly 1,200 women, it produced statistically significant improvements in both desire and the distress that low desire causes, compared with placebo.

It's an approved medication with Phase 3 data behind it, reviewed and prescribed by a licensed U.S. physician and compounded by a licensed U.S. pharmacy. The thing separating it from the concierge tier was never the science. It was the price, and the quiet assumption that you had to know the right doctor to be offered it at all.

you don't need a concierge doctor to be taken seriously

What the wealthiest patients are actually buying isn't a secret molecule. It's access and attention: a clinician who takes the complaint seriously, screens properly, and follows up. That part is not expensive to reproduce. It's just usually withheld.

With Pepvio, the online visit takes about 2 minutes. A licensed U.S. physician reviews your history, decides whether PT-141 is appropriate, and screens for the contraindications that matter. If it's a fit, a licensed U.S. pharmacy compounds it and ships it to your door. You only pay for the medication if a physician actually prescribes it, and the review itself costs nothing. No membership, no retainer, no concierge tier.

If you're still orienting, what actually moves female libido lays out the full landscape, and the female-Viagra question covers why the men's playbook doesn't map cleanly onto women.

sexual health is health, at any income

The billionaires in that article aren't smarter than everyone else about their own bodies. They just have someone in their corner who refuses to wave off low desire as inevitable. The insight is theirs to share, not to hoard: desire is part of health, it's worth treating, and a verdict of "that's just how it is now" is not the end of the conversation.

You can act on that same insight this week, without the $30,000 doctor.